Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

This publication has 26 references indexed in Scilit:

• Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2022
• O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
  Annals of Oncology, 2022
• Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study
  European Journal of Cancer, 2022
• Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
  JAMA Oncology, 2021
• Practical considerations in screening for genetic alterations in cholangiocarcinoma
  Annals of Oncology, 2021
• Prevention and treatment of FGFR inhibitor-associated toxicities
  Critical Reviews in Oncology/Hematology, 2020
• Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5
  European Journal of Cancer, 2015
• Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
  Human Pathology, 2014
• Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
  Hepatology, 2013
• Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
  Journal of Hepatology, 2012